Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
Open Access
- 10 March 2008
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 83 (8), 614-617
- https://doi.org/10.1002/ajh.21191
Abstract
High‐dose therapy and autologous stem cell transplant (HDT) have been shown to prolong survival in multiple myeloma (MM) in randomized trials, but only included patients of 65 years or younger. Given the median age at diagnosis of 66 years, it is important to have a better understanding of the outcome of transplantation in the older patients. We identified 33 patients with MM, who were ≥70 years at the time of their HDT. We matched them to a group of 60 patients, 65 years or younger, (two controls for each patient), based on time to transplant, disease status at transplant, Durie‐Salmon stage, labeling index, presence of cytogenetic abnormalities, and presence of circulating plasma cells. The median age of the two groups were 55.6 (range, 37.3–64.9) and 71.7 (range 70–75.8) years at transplant. Although more of the older patients received dose reduced melphalan, the overall response rate was similar (97% vs. 98%) as was the median time to progression (28.5 months vs. 17.8 months, P = 0.7) for the elderly group compared to the younger patients. The median overall survival from transplant was not reached for the elderly patient group compared to 53.2 months for the younger patients, P = 0.7. HDT is feasible in selected patients with multiple myeloma over 70 years. The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age. Am. J. Hematol., 2008.Keywords
This publication has 24 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocolBone Marrow Transplantation, 2006
- Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of ageBone Marrow Transplantation, 2003
- Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimenBritish Journal of Haematology, 2003
- The role of autologous transplantation in patients with multiple myeloma aged 65 years and overBone Marrow Transplantation, 2000
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myelomaBone Marrow Transplantation, 1998
- Multiple MyelomaNew England Journal of Medicine, 1997
- Long-Term Survival in Multiple MyelomaNew England Journal of Medicine, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958